Trial Profile
A Phase 3b Extension Study of Adjunctive ALKS 5461 in the Treatment of Refractory Major Depressive Disorder
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Jul 2021
Price :
$35
*
At a glance
- Drugs Buprenorphine/samidorphan (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Alkermes plc
- 18 May 2020 Status changed from recruiting to discontinued.
- 15 Aug 2018 Status changed from not yet recruiting to recruiting.
- 06 Aug 2018 New trial record